 ALLSCHWIL, Switzerland, March 05, 2021 GLOBE NEWSWIRE -- Polyphor AG SIX: POLN a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced its financial results for the full-year of 2020 and provided a business update. 